FDA Approves Advanced DBS System Allowing More Personalized Care

FDA Approves Advanced DBS System Allowing More Personalized Care

296085

FDA Approves Advanced DBS System Allowing More Personalized Care

The U.S. Food and Drug Administration (FDA) has approved Medtronic‘s SenSight Directional Lead System, which offers both sensing and directional capabilities allowing for more precise use of deep brain stimulation (DBS), a widely approved surgical treatment for Parkinson’s disease. The first SenSight directional lead systems were implanted in a patient at the University of Florida this month, and the system is now being launched across the U.S., Medtronic reported. The system also recently received CE Mark —…

You must be logged in to read/download the full post.